Autoinducer-2 inhibitory composition, biofilm formation inhibitory composition, and topical composition

A composition of star fruit leaf and carrot extracts, potentially with a fungicide, addresses the challenge of inhibiting AI-2 and biofilms, enhancing antibacterial efficacy against protected bacteria.

JP2024166665APending Publication Date: 2024-11-29KOBAYASHI PHARMA CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2023082899
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-19
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing technologies lack effective ingredients to inhibit autoinducer-2 (AI-2) and biofilm formation, leading to reduced efficacy of antibacterial agents against bacteria protected by biofilms, particularly in conditions like acne and infectious diseases.

Method used

A composition containing star fruit leaf extract and carrot extract, optionally with a fungicide, is developed to inhibit AI-2 and biofilm formation, enhancing bactericidal activity against bacteria like Cutibacterium acnes and Pseudomonas.

Benefits of technology

The composition effectively inhibits quorum sensing and biofilm formation, improving the efficacy of antibacterial agents by ensuring they penetrate and act on bacteria protected by biofilms, thereby treating conditions such as acne and infectious diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024166665000001
    Figure 2024166665000001
  • Figure 2024166665000002
    Figure 2024166665000002
  • Figure 2024166665000003
    Figure 2024166665000003
Patent Text Reader

Abstract

To provide an AI-2 inhibitory composition.SOLUTION: An autoinducer-2 inhibitory composition contains (A) an Averrhoa carambola leaf extract and (B) a Panax ginseng extract and / or a Phellodendron amurense Ruprecht extract.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to a composition for inhibiting autoinducer-2, a composition for inhibiting biofilm formation, and a composition for topical use. [Background technology]

[0002] Quorum sensing is a microbial signaling mechanism that senses the density of bacteria by sensing the extracellular concentration of autoinducers, which are signal substances produced by the same bacteria, and controls specific gene expression and phenotype accordingly. Quorum sensing is known to be involved in bacterial infection, pathogenicity expression, biofilm formation, toxin production, etc.

[0003] For example, many pathogenic bacteria, such as Streptococcus mutans, which causes dental caries, Porphyromonas gingivalis, which causes periodontal disease, Helicobacter pylori, which causes gastric ulcers and gastric cancer, and Clostridium perfringens, which causes food poisoning and hemorrhagic enteritis, use autoinducer-2 (AI-2), a signal molecule, to control quorum sensing. Therefore, by using an AI-2 inhibitor, it is possible to inhibit quorum sensing in these pathogenic bacteria, and as a result, it is expected that various infectious diseases caused by these pathogenic bacteria can be prevented or treated.

[0004] It is also believed that quorum sensing is involved in the development of acne (acne vulgaris). Specifically, it has been reported that the production of AI-2 by Cutibacterium acnes increases in the biofilm formed in the hair follicle, promoting the decomposition of sebum by lipase and increasing the factors that exacerbate acne (see Non-Patent Document 1). In addition, for the prevention or treatment of acne, it is effective to suppress the proliferation of acne bacteria with drugs such as antibacterial agents, but since acne bacteria are protected by a biofilm formed in the hair follicle, even if the drug is applied percutaneously, the biofilm prevents the penetration of the drug, reducing its efficacy. It is expected that the formation of the biofilm of acne bacteria is suppressed by inhibiting the quorum sensing of acne bacteria with an AI-2 inhibitor, and as a result, the efficacy of acne prevention or treatment drugs is enhanced.

[0005] Various components that have inhibitory activity against AI-2 have been studied. For example, Patent Document 1 lists 5-amino-n-valeric acid, butane-1,4-diamine, guanine, acetoacetic acid, γ-hydroxybutyric acid, piperidine, gluconic acid, 3-hydroxy-3-methylglutaric acid, N 8 It is disclosed that 5-acetylspermidine and urocanic acid, as well as salts thereof, can be used as AI-2 inhibitors. In addition, Patent Document 2 discloses that 4,5-dihydroxy-2-cyclopenten-1-one can be used as an AI-2 inhibitor.

[0006] However, in order to further improve the inhibitory activity of AI-2 and biofilm formation inhibitory activity, and to keep up with the diversification of products that have AI-2 inhibitory activity and biofilm formation inhibitory activity, there is a strong demand for the development of new components that can be used as AI-2 inhibitors or biofilm formation inhibitors. [Prior art documents] [Non-patent literature]

[0007] [Non-Patent Document 1] SM Lwin et al., Acne, quorum sensing and danger, Clinical and Experimental Dermatology, Volume 39, Issue 2, p.162-167, 13 February 13 2014 [Patent documents]

[0008] [Patent Document 1] JP 2012-97036 A [Patent Document 2] WO 2003 / 77844 Summary of the Invention [Problem to be solved by the invention]

[0009] An object of the present disclosure is to provide a composition for inhibiting AI-2. Another object of the present disclosure is to provide a composition for inhibiting biofilm formation. Still another object of the present disclosure is to provide a composition for external use that exhibits bactericidal activity against bacteria in a biofilm. [Means for solving the problem]

[0010] The present inventors conducted intensive research to solve the above problems, and found that a composition containing (A) star fruit leaf extract and (B) carrot extract and / or Phellodendron bark extract has excellent inhibitory activity against AI-2 and has an effect of suppressing the formation of biofilms formed on the skin or mucous membranes, and found that it can be used as an active ingredient of a composition for inhibiting AI-2 or a composition for suppressing biofilm formation. Furthermore, the present inventors found that a composition containing (A) star fruit leaf extract and (B) carrot extract and / or Phellodendron bark extract has an effect of enhancing the bactericidal action of a bactericide against bacteria in a biofilm, in addition to the effect of suppressing the formation of a biofilm. The present disclosure was completed based on such findings and through further research.

[0011] That is, in one embodiment of the present disclosure, there is provided the invention having the following aspects. Item 1-1. A composition for inhibiting AI-2 comprising (A) star fruit leaf extract and (B) carrot extract and / or Phellodendron Bark extract. Item 1-2. The composition for inhibiting AI-2 according to Item 1-1, further comprising a fungicide (C). Item 1-3. A composition for inhibiting AI-2 according to Item 1-1 or 1-2, which is used to inhibit AI-2 in at least one bacterium selected from the group consisting of Cutibacterium bacteria, Pseudomonas bacteria, and Vibrio bacteria. Item 1-4. The composition for inhibiting AI-2 according to any one of Items 1-1 to 1-3, which is an external preparation for skin. Item 1-5. A composition for inhibiting AI-2 according to any one of Items 1-1 to 1-4, which is applied to skin in which prevention or treatment of acne is required. Item 1-6. Use of a composition comprising (A) star fruit leaf extract and (B) carrot extract and / or Phellodendron Bark extract for the manufacture of a composition for inhibiting AI-2. Item 1-7. A method for inhibiting AI-2, comprising applying an effective amount of a composition for inhibiting AI-2, comprising (A) starfruit leaf extract and (B) carrot extract and / or Phellodendron Bark extract, to a body part where AI-2 inhibition is desired. Item 1-8. A composition comprising (A) star fruit leaf extract and (B) carrot extract and / or phellodendron bark extract, for use in a treatment for inhibiting AI-2. Item 1-9. Non-therapeutic use of a composition comprising (A) star fruit leaf extract and (B) carrot extract and / or Phellodendron Bark extract for inhibiting AI-2.

[0012] In addition, other embodiments of the present disclosure provide the following aspects of the invention. Item 2-1. A composition for inhibiting biofilm formation, comprising (A) starfruit leaf extract and (B) carrot extract and / or Phellodendron Bark extract. Item 2-2. The composition for inhibiting biofilm formation according to Item 2-1, further comprising a bactericide (C). Item 2-3. A composition for inhibiting biofilm formation according to Item 2-1 or 2-2, which is used to inhibit biofilm formation by bacteria of the genus Cutibacterium and / or bacteria of the genus Pseudomonas. Item 2-4. The composition for inhibiting biofilm formation according to any one of Items 2-1 to 2-3, which is an external preparation for skin. Item 2-5. A composition for inhibiting biofilm formation according to any one of Items 2-1 to 2-4, which is applied to skin in which prevention or treatment of acne is required. Item 2-6. Use of a composition comprising (A) star fruit leaf extract and (B) carrot extract and / or Phellodendron Bark extract for the manufacture of a composition for inhibiting biofilm formation. Item 2-7. A method for inhibiting biofilm formation, comprising applying an effective amount of a composition for inhibiting biofilm formation, comprising (A) starfruit leaf extract and (B) carrot extract and / or phellodendron bark extract, to a body part where inhibition of biofilm formation is desired. Item 2-8. A composition comprising (A) starfruit leaf extract and (B) carrot extract and / or phellodendron bark extract, for use in a treatment for inhibiting biofilm formation. Item 2-9. Non-therapeutic use of a composition comprising (A) star fruit leaf extract and (B) carrot extract and / or Phellodendron Bark extract for inhibiting biofilm formation.

[0013] In still another embodiment of the present disclosure, there is provided the invention having the following aspects. Item 3-1. A composition for external use comprising (A) starfruit leaf extract, (B) carrot extract and / or Phellodendron Bark extract, and (C) a bactericide. Item 3-2. The composition for external use according to Item 3-1, which is used to kill bacteria in a biofilm. Item 3-3. The composition for external use according to Item 3-1 or 3-2, which is used for killing Cutibacterium bacteria and / or Pseudomonas bacteria in a biofilm. Item 3-4. The composition for external use according to any one of Items 3-1 to 3-3, which is an external preparation for skin. Item 3-5. The composition for external use according to any one of Items 3-1 to 3-4, which is used for preventing or treating acne. Item 3-6. Use of a composition comprising (A) star fruit leaf extract, (B) carrot extract and / or Phellodendron Bark extract, and (C) a bactericide for the manufacture of a composition for external use. Item 3-7. The use according to Item 3-6, wherein the topical composition is used to kill bacteria in a biofilm. Item 3-8. A method for killing bacteria in a biofilm, comprising applying an effective amount of an external composition containing (A) starfruit leaf extract, (B) carrot extract and / or phellodendron bark extract, and (C) a bactericide to a body part where a biofilm is formed. Item 3-9. A composition used in a treatment for killing bacteria in a biofilm, comprising (A) a starfruit leaf extract, (B) a carrot extract and / or an oak bark extract, and (C) a bactericide. Item 3-10. Non-therapeutic use of a composition comprising (A) starfruit leaf extract, (B) carrot extract and / or Phellodendron Bark extract, and (C) a bactericide for killing bacteria in a biofilm. Effect of the Invention

[0014] According to the AI-2 inhibitory composition of the present disclosure, AI-2 can be inhibited, so that quorum sensing of bacteria occurring on the skin or mucous membrane can be inhibited. In addition, according to the biofilm formation inhibitory composition of the present disclosure, the formation of a biofilm formed on the skin or mucous membrane can be effectively inhibited. For example, acne bacteria that cause acne are protected by a biofilm formed in a hair follicle, and in the conventional technology, even if a preventive or therapeutic agent for acne (e.g., a bactericide against acne bacteria) is applied percutaneously, the penetration of the preventive or therapeutic agent is hindered by the biofilm, and the preventive or therapeutic effect of acne cannot be fully exerted. However, by applying the AI-2 inhibitory composition or the biofilm formation inhibitory composition of the present disclosure to the skin where acne prevention or treatment is required, the formation of a biofilm of acne bacteria can be inhibited, and the preventive or therapeutic effect of acne by the preventive or therapeutic agent can be effectively expressed.

[0015] Furthermore, the topical composition disclosed herein can effectively exert a bactericidal effect against bacteria in biofilms. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0016] In this disclosure, the notation "X to Y" regarding a numerical range refers to a range from X to Y inclusive.

[0017] 1. AI-2 Inhibitory Composition The AI-2 inhibitory composition of the present disclosure is characterized by comprising (A) star fruit leaf extract and (B) carrot extract and / or Phellodendron Bark extract. The AI-2 inhibitory composition of the present disclosure is described in detail below.

[0018] [(A) Starfruit Leaf Extract] The AI-2 inhibiting composition of the present disclosure contains starfruit leaf extract.

[0019] Star fruit is a plant with the scientific name Averrhoa carambola. Star fruit leaf extract is an extract obtained by performing an extraction process using star fruit leaves as an extraction raw material, and is also called golesin leaf extract. Star fruit leaves to be subjected to the extraction process may be in a raw state as is, or may be subjected to pretreatment such as crushing, cutting, steaming, rolling, drying, roasting, etc., as necessary.

[0020] The extraction process for obtaining star fruit leaf extract may be a general extraction method used in the production of plant extracts, such as solvent extraction, supercritical extraction, steam distillation, etc. Among these, the solvent extraction is preferred.

[0021] Examples of the extraction solvent used in the solvent extraction treatment include water, lower alcohols such as ethanol, polyhydric alcohols such as propylene glycol and 1,3-butylene glycol, hydrophilic solvents such as acetone, and mixed solvents thereof. Among these extraction solvents, preferred are water, polyhydric alcohols, and mixed solvents thereof, more preferred are water, 1,3-butylene glycol, and mixed solvents thereof, and particularly preferred is a mixed solvent of water and 1,3-butylene glycol.

[0022] Furthermore, when a mixed solvent of water and a polyhydric alcohol is used as the extraction solvent, the ratio of water to polyhydric alcohol in the mixed solvent is not particularly limited, but examples of the weight ratio of water:polyhydric alcohol include 5:95 to 95:5, preferably 30:70 to 90:10, and more preferably 60:40 to 80:20.

[0023] The solvent extraction process may be carried out by immersing star fruit leaves in an extraction solvent and stirring as necessary, and the amount of star fruit leaves to be immersed in the extraction solvent, the extraction time, etc. may be appropriately set. The solvent extraction process may also be carried out under heating conditions.

[0024] After the extraction process, the solid matter is removed by solid-liquid separation to obtain an extract (extract liquid) of star fruit leaves. The extract liquid obtained by the extraction process may be purified by filtration or adsorption treatment such as various types of chromatography using columns filled with carriers such as polystyrene gel (polystyrene-divinylbenzene copolymer, etc.), ion exchange resin, activated carbon, etc., as necessary. The obtained extract liquid may be used as it is as a non-concentrated extract, or may be subjected to a concentration process as necessary to use it as a soft extract, or may be subjected to a drying process to use it as an extract powder.

[0025] The content of starfruit leaf extract in the AI-2 inhibitory composition of the present disclosure may be set appropriately depending on the dosage form and product shape of the AI-2 inhibitory composition, and may be, for example, 0.0001 to 1 wt%, preferably 0.0001 to 0.5 wt%, and more preferably 0.0001 to 0.2 wt%, calculated as the dry weight of the starfruit leaf extract.

[0026] [(B) Carrot extract and / or Phellodendron bark extract] The AI-2 inhibitory composition of the present disclosure contains starfruit leaf extract, carrot extract, and / or phellodendron bark extract. Although starfruit leaf extract, carrot extract, and phellodendron bark extract do not exhibit AI-2 inhibitory activity by themselves, the combined use of starfruit leaf extract and carrot extract and / or phellodendron bark extract makes it possible to exert the AI-2 inhibitory activity.

[0027] Carrot, scientific name Panax ginseng, also called Panax ginseng (Japanese name), is a perennial plant belonging to the genus Panax in the family Araliaceae. Carrot extract is an extract obtained by extracting the whole plant or root (preferably the root) of carrot. The raw material part of carrot subjected to the extraction process may be in a raw state as it is, but may be subjected to pretreatment such as crushing, cutting, steaming, rolling, drying, roasting, etc., as necessary.

[0028] Phellodendron amurense Ruprecht is a deciduous tall tree belonging to the genus Phellodendron of the family Lisaceae. Phellodendron extract is an extract obtained by extracting Phellodendron. The raw material parts of Phellodendron that are subjected to the extraction process include bark, leaves, stems, flowers, fruits, peels, pits, or mixtures of these parts, and preferably bark. The raw material parts of Phellodendron that are subjected to the extraction process may be in a raw state as they are, or may be subjected to pretreatment such as crushing, cutting, steaming, rolling, drying, and roasting, as necessary.

[0029] The extraction process for obtaining the carrot extract or the phellodendron bark extract may be a general extraction method used in the production of plant extracts, such as solvent extraction, supercritical extraction, steam distillation, etc. Among these, the solvent extraction is preferred.

[0030] Examples of extraction solvents used in the solvent extraction process to obtain carrot extract or Phellodendron bark extract include water, lower alcohols such as ethanol, polyhydric alcohols such as propylene glycol and 1,3-butylene glycol, hydrophilic solvents such as acetone, and mixed solvents thereof. Among these extraction solvents, preferred are water, polyhydric alcohols, and mixed solvents thereof, more preferred are water, 1,3-butylene glycol, and mixed solvents thereof, and particularly preferred is a mixed solvent of water and 1,3-butylene glycol.

[0031] When a mixed solvent of water and polyhydric alcohol is used as the extraction solvent to obtain a carrot extract, the ratio of water to polyhydric alcohol in the mixed solvent is not particularly limited, but examples of the ratio include a water:polyhydric alcohol weight ratio of 5:95 to 95:5, preferably 20:80 to 80:20, and more preferably 50:50 to 70:30.

[0032] Furthermore, when a mixed solvent of water and polyhydric alcohol is used as the extraction solvent to obtain Phellodendron bark extract, the ratio of water to polyhydric alcohol in the mixed solvent is not particularly limited, but may be, for example, a weight ratio of water:polyhydric alcohol of 5:95 to 95:5, preferably 20:80 to 80:20, and more preferably 40:60 to 60:40.

[0033] The solvent extraction process for obtaining a carrot extract or an oak bark extract may be carried out by immersing each plant raw material part in an extraction solvent and stirring as necessary, and the amount of each plant raw material part immersed in the extraction solvent, the extraction time, etc. may be appropriately set. The solvent extraction process may also be carried out under heating conditions.

[0034] After the extraction process, solid matter is removed by solid-liquid separation to obtain a carrot or phellodendron extract (extract). The extract obtained by the extraction process may be purified as necessary by filtering or by adsorption using columns filled with carriers such as polystyrene gel (polystyrene-divinylbenzene copolymer, etc.), ion exchange resin, and activated carbon. The extract obtained may be used as it is as a non-concentrated extract, or may be used as a soft extract by subjecting it to a concentration process as necessary, or may be used as an extract powder by subjecting it to a drying process.

[0035] In the AI-2 inhibitory composition of the present disclosure, one of the carrot extract and the Phellodendron Bark extract may be used alone, or they may be used in combination.

[0036] In the AI-2 inhibitory composition of the present disclosure, the ratio of starfruit leaf extract to carrot extract and / or Phellodendron Bark extract is not particularly limited, but may be, for example, 0.1 to 50 parts by weight, preferably 0.2 to 30 parts by weight, more preferably 0.5 to 25 parts by weight or 0.5 to 5 parts by weight of carrot extract per 1 part by weight of starfruit leaf extract in dry weight terms; or 0.1 to 70 parts by weight, preferably 0.2 to 60 parts by weight, more preferably 0.5 to 50 parts by weight or 0.5 to 5 parts by weight of Phellodendron Bark extract in dry weight terms.

[0037] The contents of carrot extract and Phellodendron bark extract in the AI-2 inhibitory composition of the present disclosure may be set appropriately depending on the dosage form and product form of the AI-2 inhibitory composition, for example, in the case of carrot extract, the content is 0.0001 to 1 wt %, preferably 0.0001 to 0.5 wt %, and more preferably 0.0001 to 0.2 wt %, calculated as the dry weight of the carrot extract; and in the case of Phellodendron bark extract, the content is 0.0001 to 1 wt %, preferably 0.0001 to 0.5 wt %, and more preferably 0.0001 to 0.2 wt %, calculated as the dry weight of the Phellodendron bark extract.

[0038] [(C) Fungicide] In addition to the above-mentioned components, the AI-2 inhibitor composition of the present disclosure may contain a bactericide (C). When the AI-2 inhibitor composition of the present disclosure contains a bactericide, it is possible to enhance and exert the bactericidal action of the bactericide against bacteria in the biofilm. The type of bactericide is not particularly limited as long as it is applicable to the body, and examples of the bactericide include phenol-based bactericides such as isopropyl methylphenol (Biosol) and phenol; pyridine-based bactericides such as zinc pyrithione and sodium pyrithione; and cationic bactericides such as benzalkonium chloride, cetylpyridinium chloride, benzethonium chloride, and dequalinium chloride. These bactericides may be used alone or in combination of two or more.

[0039] When the AI-2 inhibitory composition of the present disclosure contains a fungicide, the content of the fungicide in the AI-2 inhibitory composition may be set appropriately depending on the formulation and product form of the AI-2 inhibitory composition, and may be, for example, 0.01 to 1 weight %, preferably 0.01 to 0.5 weight %, and more preferably 0.01 to 0.2 weight %.

[0040] [Other ingredients] The AI-2 inhibitory composition of the present disclosure may contain other additives, medicinal ingredients, bases, etc. that are incorporated into topical skin preparations, oral care products, etc.

[0041] [Dosage form and product shape of AI-2 inhibitor composition] The dosage form of the AI-2 inhibitory composition of the present disclosure is not particularly limited, and may be any of solid, semi-solid, or liquid.

[0042] The AI-2 inhibitor composition of the present disclosure is provided in a product form that can be applied to the body.Specific examples of the product form of the AI-2 inhibitor composition of the present disclosure include skin topical preparations, oral care products, and internal medicines.Among these, preferred is the skin topical preparation.

[0043] When the AI-2 inhibitory composition of the present disclosure is provided as a skin topical preparation, it may be prepared in a desired form by combining starfruit leaf extract, carrot extract and / or Phellodendron bark extract with other additives, medicinal ingredients, etc. Examples of skin topical preparations include skin topical medicines and cosmetics, and specific examples thereof include skin topical medicines such as creams, lotions, gels, emulsions, liquids, poultices, patches, liniments, aerosols, aqueous ointments, and packs; and cosmetics such as aqueous ointments, creams, emulsions, lotions, packs, and gels. Among these, preferred are skin topical medicines.

[0044] Furthermore, when the AI-2 inhibitory composition of the present disclosure is provided as an oral care product, it may be prepared into a desired form by combining the starfruit leaf extract, carrot extract and / or Phellodendron Bark extract with other additive ingredients, medicinal ingredients, etc. The oral care product may be any product that can be applied to the oral cavity and remain there for a certain period of time, and specific examples thereof include oral hygiene products such as liquid dentifrices, toothpastes, mouthwashes, mouth fresheners (mouth sprays, etc.), oral pastes, and gum massage creams.

[0045] [Application] The AI-2 inhibitory composition of the present disclosure is used to inhibit AI-2 in bacteria that control quorum sensing using AI-2 as a signal substance. The AI-2 inhibitor of the present disclosure can inhibit quorum sensing by inhibiting AI-2 of the bacteria. As a result, the AI-2 inhibitory composition of the present disclosure can suppress pathogenic expression, biofilm formation, toxin production, etc., and has a preventive or therapeutic effect on infectious diseases caused by the bacteria. Therefore, the AI-2 inhibitory composition of the present disclosure can be used as a preventive or therapeutic agent for infectious diseases caused by the bacteria by applying it to a body part (intraoral cavity, skin, etc.) where bacteria that control quorum sensing using AI-2 as a signal substance are present. Furthermore, when the AI-2 inhibitory composition of the present disclosure contains a bactericide, the bactericidal action of the bactericide can be effectively exerted against the bacteria in the biofilm by inhibiting the quorum sensing of the bacteria, so that it can also be used for the purpose of killing bacteria in the biofilm.

[0046] Examples of bacteria that control quorum sensing using AI-2 as a signal substance include Cutibacterium bacteria such as Cutibacterium acnes (acne bacteria); Pseudomonas bacteria such as Pseudomonas aeruginosa (Pseudomonas aeruginosa); Vibrio bacteria such as Vibrio harveyi, Vibrio cholerae, and Vibrio fischeri; Streptococcus bacteria such as Streptococcus mutans, Streptococcus pneumoniae, Streptococcus gordonii, Streptococcus oralis, Streptococcus sobrinus, and Streptococcus anginosus; Porphyromonas bacteria such as Porphyromonas gingivalis; and Clostridium perfringens and Clostridium difficile. Examples of bacteria that may be affected include Rostridium bacteria; Helicobacter bacteria such as Helicobacter pylori; Enterobacter bacteria such as Enterobacter cloacae; Staphylococcus bacteria such as Staphylococcus aureus; Salmonella bacteria such as Salmonella enterica and Salmonella typhimurium; Campylobacter bacteria such as Campylobacter jejuni and Campylobacter coli; Escherichia bacteria such as Escherichia coli; Actinomyces bacteria such as Actinomyces naeslundii; Fusobacterium bacteria such as Fusobacterium nucleatum; Aggregatibacter bacteria such as Aggregatibacter actinomycetemcomitans; and Prevotella bacteria such as Prevotella intermedia. Among these, bacteria to which the AI-2 inhibitor of the present disclosure is applied preferably include bacteria of the genus Cutibacterium, Pseudomonas, and Vibrio.

[0047] For example, the AI-2 inhibitory composition of the present disclosure can inhibit the quorum sensing of Propionibacterium acnes by inhibiting AI-2. As a result, the AI-2 inhibitory composition of the present disclosure can suppress the formation of a biofilm of Propionibacterium acnes and the progression of acne symptoms. Therefore, the AI-2 inhibitory composition of the present disclosure can be used for the purpose of preventing or treating acne. Furthermore, by suppressing the formation of a biofilm of Propionibacterium acnes, it is possible to make it easier for a preventive or therapeutic agent for acne (e.g., a bactericide against Propionibacterium acnes) to act on Propionibacterium acnes, so the AI-2 inhibitory composition of the present disclosure can also be used for the purpose of improving the efficacy of a preventive or therapeutic agent for acne. In addition, when the AI-2 inhibitory composition of the present disclosure contains a bactericide, the bactericide can effectively exert the bactericidal action of the bactericide against Propionibacterium acnes in the biofilm, so it can also be used for the purpose of killing Propionibacterium acnes in the biofilm.

[0048] The AI-2 inhibitory composition of the present disclosure can inhibit the AI-2 of Pseudomonas aeruginosa, thereby suppressing the toxin production of Pseudomonas aeruginosa. Therefore, the AI-2 inhibitory composition of the present disclosure can be used as a prophylactic or therapeutic agent for Pseudomonas aeruginosa infection. In addition, when the AI-2 inhibitory composition of the present disclosure contains a bactericide, the bactericidal action of the bactericide can be effectively exerted against Pseudomonas aeruginosa in a biofilm, so that it can also be used for the purpose of killing Pseudomonas aeruginosa in a biofilm.

[0049] The AI-2 inhibitory composition of the present disclosure can inhibit quorum sensing of Streptococcus mutans by inhibiting AI-2. As a result, the formation of a biofilm that causes dental caries and the acquisition of acid resistance by the bacteria can be suppressed, so the AI-2 inhibitory composition of the present disclosure can be used as a preventive or therapeutic agent for dental caries. In addition, when the AI-2 inhibitory composition of the present disclosure contains a bactericide, the bactericide can effectively exert its bactericidal action on Streptococcus mutans in a biofilm, so that it can also be used in combination with a bactericide for the purpose of killing Streptococcus mutans in a biofilm.

[0050] The AI-2 inhibitory composition of the present disclosure can inhibit quorum sensing by inhibiting AI-2 of Porphyromonas gingivalis, Streptococcus gordonii, Fusobacterium nucleatum, Aggregatibacter actinomycetemcomitans, or Prevotella intermedii. As a result, the formation of biofilms that cause periodontal disease and the production of toxins by the bacteria can be suppressed, so the AI-2 inhibitory composition of the present disclosure can be used as a preventive or therapeutic agent for periodontal disease. In addition, when the AI-2 inhibitory composition of the present disclosure contains a bactericide, the bactericide can effectively exert its bactericidal action on the periodontal disease bacteria in the biofilm, so it can also be used for the purpose of killing periodontal disease bacteria in the biofilm.

[0051] The AI-2 inhibitory composition of the present disclosure can inhibit quorum sensing by inhibiting AI-2 of Actinomyces naeslundii. As a result, the formation of a biofilm that causes dental caries or periodontal disease can be suppressed, and the AI-2 inhibitory composition of the present disclosure can be used as a preventive agent for dental caries or periodontal disease. In addition, when the AI-2 inhibitory composition of the present disclosure contains a bactericide, the bactericidal action of the bactericide can be effectively exerted against Actinomyces naeslundii in a biofilm, and therefore the composition can be used in combination with the bactericide to kill Actinomyces naeslundii in a biofilm.

[0052] The AI-2-inhibiting composition of the present disclosure can inhibit quorum sensing by inhibiting AI-2 in food poisoning bacteria such as Salmonella enterica, Salmonella typhimurium, Campylobacter jejuni, Campylobacter coli, and Escherichia coli. As a result, the production of toxins that cause food poisoning can be suppressed, and the AI-2-inhibiting composition of the present disclosure can be used as an agent for preventing or treating food poisoning.

[0053] The AI-2 inhibitory composition of the present disclosure can suppress the production of enterotoxins in the intestine by inhibiting AI-2 of Clostridium perfringens, and therefore can be used as a preventive or therapeutic agent for food poisoning, hemorrhagic enteritis, or gas gangrene.

[0054] The AI-2 inhibitory composition of the present disclosure inhibits AI-2 of Helicobacter pylori, thereby inhibiting the production of urease and suppressing the colonization of the bacterium in the stomach, and therefore can be used as an agent for preventing or treating gastritis, gastric ulcer, or gastric cancer.

[0055] The AI-2 inhibitory composition of the present disclosure can inhibit AI-2 in Enterobacter bacteria, thereby suppressing the production of Shiga toxin in enterohemorrhagic Escherichia coli, and therefore can be used as a prophylactic or therapeutic agent for enterohemorrhagic colon infections.

[0056] 2. Composition for inhibiting biofilm formation The composition for inhibiting biofilm formation of the present disclosure is characterized by containing (A) star fruit leaf extract and (B) carrot extract and / or Phellodendron Bark extract. The composition for inhibiting biofilm formation of the present disclosure will be described in detail below.

[0057] [Ingredients included] The composition for inhibiting biofilm formation of the present disclosure contains (A) starfruit leaf extract and (B) carrot extract and / or Phellodendron bark extract. The preparation method, content, etc. of these plant extracts are the same as those of the above-mentioned "1. Composition for inhibiting AI-2."

[0058] In addition, the composition for inhibiting biofilm formation of the present disclosure may contain a bactericide. When the composition for inhibiting biofilm formation of the present disclosure contains a bactericide, the bactericidal action of the bactericide against bacteria in the biofilm can be enhanced. The type and content of the bactericide used are the same as those in the above "1. Composition for inhibiting AI-2".

[0059] In addition, the composition for inhibiting biofilm formation of the present disclosure may contain other additive ingredients, medicinal ingredients, bases, etc. that are incorporated into topical skin preparations, oral care products, etc.

[0060] [Formulation and product shape of biofilm formation suppressing composition] The dosage form and product shape of the composition for inhibiting biofilm formation of the present disclosure are the same as those of "1. Composition for inhibiting AI-2" above.

[0061] [Application] The composition for inhibiting biofilm formation of the present disclosure is applied to a body part where a biofilm is formed (skin, oral cavity, etc.) or a body part where a biofilm may be formed (skin, oral cavity, etc.) for the purpose of inhibiting the formation of a biofilm by bacteria. Since biofilms on the skin and mucous membranes are involved in the protection of pathogenic bacteria, the expression of bacterial pathogenicity, the production of bacterial toxins, etc., the skin and mucous membranes can be made healthy by inhibiting the formation of a biofilm on the skin and mucous membranes. In addition, when the composition for inhibiting biofilm formation of the present disclosure contains a bactericide, the bactericide can effectively exert its bactericidal action on the bacteria in the biofilm, so it can also be used for the purpose of sterilizing the bacteria in the biofilm.

[0062] In the composition for inhibiting biofilm formation of the present disclosure, the type of causative bacteria of biofilms to be inhibited is not particularly limited, and examples thereof include those exemplified as bacteria that control quorum sensing in the above "1. Composition for inhibiting AI-2". In the composition for inhibiting biofilm formation of the present disclosure, suitable examples of causative bacteria of biofilms to be inhibited include bacteria of the genus Cutibacterium, such as Cutibacterium acnes, and bacteria of the genus Pseudomonas, such as Pseudomonas aeruginosa.

[0063] For example, by inhibiting the formation of a biofilm of P. acnes, the progression of acne symptoms can be inhibited, so the biofilm formation-inhibiting composition of the present disclosure can be used for the purpose of preventing or treating acne. In addition, by inhibiting the formation of a biofilm of P. acnes, it is possible to make it easier for a preventive or therapeutic agent for acne (e.g., an antibacterial agent for P. acnes) to act on P. acnes, so the biofilm formation-inhibiting composition of the present disclosure can also be used for the purpose of improving the efficacy of a preventive or therapeutic agent for acne. Furthermore, when the biofilm formation-inhibiting composition of the present disclosure contains a bactericide, it can also be used for the purpose of killing P. acnes in a biofilm. In addition, by inhibiting the formation of a biofilm of P. aeruginosa, the toxin-producing ability of P. aeruginosa can be reduced, so the biofilm formation-inhibiting composition of the present disclosure can be used as a preventive or therapeutic agent for P. aeruginosa infection. Furthermore, when the biofilm formation-inhibiting composition of the present disclosure contains a bactericide, it can also be used for the purpose of killing P. aeruginosa in a biofilm. In addition, since biofilms formed in the oral cavity cause dental caries or periodontal disease, the composition for inhibiting biofilm formation of the present disclosure can also be used as a preventive or therapeutic agent for dental caries. Furthermore, when the composition for inhibiting biofilm formation of the present disclosure contains a bactericide, it can also be used for the purpose of sterilizing cariogenic bacteria or periodontal disease bacteria in the biofilm.

[0064] 3. External composition The topical composition of the present disclosure is used for the purpose of killing bacteria in a biofilm, and is characterized by comprising (A) star fruit leaf extract, (B) carrot extract and / or Phellodendron bark extract, and (C) a bactericide. The topical composition of the present disclosure will be described in detail below.

[0065] [Ingredients included] The topical composition of the present disclosure contains (A) starfruit leaf extract and (B) carrot extract and / or phellodendron bark extract. The preparation method, content, etc. of these plant extracts are the same as those of the above-mentioned "1. Composition for inhibiting AI-2."

[0066] Furthermore, the topical composition of the present disclosure contains a fungicide (C). The type and content of the fungicide are as described above in "1. Composition for inhibiting AI-2."

[0067] In addition, the topical composition of the present disclosure may contain other additive ingredients, medicinal ingredients, bases, etc. that are blended in topical skin preparations, oral care products, etc.

[0068] [Formulation and product shape of topical composition] The dosage form of the topical composition of the present disclosure is not particularly limited, and may be any of solid, semi-solid, or liquid.

[0069] In the present disclosure, a topical composition is a preparation that is applied to a body surface such as the skin or mucous membrane, and specifically includes topical skin preparations, oral care products, etc. Specific examples of topical skin preparations and oral care products are as described in the above section "1. Composition for inhibiting AI-2". A suitable example of the product form of the topical composition of the present disclosure is a topical skin preparation.

[0070] [Application] The use of the topical composition of the present disclosure is not particularly limited, but a suitable example is the use of killing bacteria in biofilm.When a biofilm is formed on the skin or in the oral cavity, the biofilm prevents the penetration of the bactericide, and the bactericide cannot fully exert its bactericidal action, but the topical composition of the present disclosure can effectively exert a bactericidal action on the bacteria in the biofilm.When the topical composition of the present disclosure is used for killing bacteria in a biofilm, the topical composition of the present disclosure can be applied to the body part (skin, oral cavity, etc.) where the biofilm is formed.

[0071] When the topical composition of the present disclosure is used for the purpose of killing bacteria in a biofilm, the type of bacteria to be killed is not particularly limited, and examples thereof include those exemplified as bacteria that control quorum sensing in the above "1. Composition for inhibiting AI-2". In the topical composition of the present disclosure, suitable examples of bacteria in a biofilm to be killed include bacteria of the genus Cutibacterium, such as Cutibacterium acnes, and bacteria of the genus Pseudomonas, such as Pseudomonas aeruginosa.

[0072] For example, since the acne prevention or treatment effect can be expected by killing acne bacteria in a biofilm, the topical composition of the present disclosure can be suitably used for the purpose of preventing or treating acne. In addition, since the preventive or treatment effect of Pseudomonas aeruginosa infection can be enhanced by effectively killing Pseudomonas aeruginosa in a biofilm, the topical composition of the present disclosure can also be suitably used for the purpose of preventing or treating Pseudomonas aeruginosa infection. In addition, since the preventive or treatment effect of caries or periodontal disease can be improved by effectively killing caries bacteria or periodontal disease bacteria in a biofilm, the topical composition of the present disclosure can also be suitably used for the purpose of preventing or treating caries or periodontal disease. EXAMPLES

[0073] The present disclosure will now be described in more detail with reference to examples, but the present invention is not limited to these examples.

[0074] The plant extracts used in the following test examples are as follows: Star Fruit Leaf Extract : Extract obtained by extracting star fruit leaves with a mixed solvent of water and 1,3-butylene glycol (weight ratio of water:1,3-butylene glycol is 7:3) Carrot Extract : Extract obtained by extracting carrot root with a mixed solvent of water and 1,3-butylene glycol (weight ratio of water:1,3-butylene glycol is 6:4) Phellodendron Bark Extract: Extract obtained by extracting Phellodendron bark with a mixed solvent of water and 1,3-butylene glycol (weight ratio of water:1,3-butylene glycol is 5:5)

[0075] Test Example 1: Verification of AI-2 inhibitory activity 1. Test Method The AI-2 inhibitory activity was measured using reporter bacteria that emit light upon recognition of AI-2. The test materials and measurement conditions used are as follows.

[0076] (1) Test materials Reporter bacteria The reporter bacterium used was Vibrio harveyi MM32 strain (ATCC BAA-1121, luxN::Cm, luxS::Tn5Ka).

[0077] ·Km-LB medium LB medium containing 10 g / L sodium chloride, 10 g / L bactotryptone, and 5 g / L yeast extract was sterilized by high-pressure steam (121°C, 15 minutes), and then kanamycin sulfate was added aseptically to a concentration of 50 mg / L to prepare Km-LB medium.

[0078] AB medium First, an aqueous solution containing 0.3 M sodium chloride, 0.05 M magnesium sulfate, and 2 g / L casamino acids (vitamin-free, Difco) was adjusted to pH 7.5 with potassium hydroxide, and then sterilized by high-pressure steam (121 ° C, 15 minutes). 100 mL of this aqueous solution was added with 1 mL of 1 M potassium phosphate buffer (a buffer adjusted to pH 7.0 by mixing 1 M potassium dihydrogen phosphate aqueous solution and 1 M dipotassium hydrogen phosphate aqueous solution), 1 mL of an aqueous solution containing 0.1 M L-arginine, 2 mL of an aqueous solution containing 50 wt% glycerol, 0.01 mL of an aqueous solution containing 0.1 mg / mL riboflavin, and 0.01 mL of an aqueous solution containing 10 mg / mL thiamine hydrochloride, and sterilized by filtration with a filter having a pore size of 0.22 μm to obtain AB medium.

[0079] ·HMF-containing liquid 2.35 mg of 4-hydroxy-5-methyl-3(2H)-furanone (HMF) (CAS: 19322-27-1), 1 mL of ethanol, and 9 mL of sterile distilled water were mixed in a glass container to prepare an HMF-containing solution (containing 2,000 μM HMF). HMF is known to have AI-2 activity, and in this test, HMF was used as an AI-2 substitute.

[0080] ·BMF-containing liquid 2.15 mg of 4-bromo-5-(4-methoxyphenyl)-2(5H)-furanone (BMF) (CAS: 32060-84-7), 4 mL of ethanol, and 36 mL of sterile distilled water were mixed to prepare a BMF-containing solution (containing 200 μM BMF). BMF is known to have the activity of inhibiting AI-2, and in this test, BMF was used as a positive control.

[0081] Specimen Each plant extract was added to an aqueous solution containing 10% by volume of ethanol at a concentration 20 times that shown in Table 1 to prepare various samples.

[0082] (2) Measurement conditions The reporter bacteria were precultured in Km-LB medium, and the optical density (OD) of the preculture solution at 600 nm was measured. 600 ) and add an appropriate amount of Km-LB medium to obtain the OD 600 The reporter bacteria solution was adjusted to 0.50, and the reporter bacteria solution was obtained. This reporter bacteria solution was diluted 2,500-fold with AB medium to obtain a reporter bacteria dilution solution.

[0083] In a sterile glass test tube, 0.9 mL of the reporter bacteria dilution solution and 0.05 mL of the sample were mixed and incubated for 10 minutes under conditions of 30°C and stirring (180 rpm) in the dark. Then, 0.05 mL of HMF-containing solution was added, and incubated for 4 hours under conditions of 30°C and stirring (180 rpm) in the dark. At this point, the sample was diluted 20 times. The final concentration listed in Table 1 is the concentration of the sample at this point. 0.1 mL of the solution after incubation was transferred to a plate for luminescence measurement, and the luminescence intensity at 578 nm (luminescence intensity of the sample) was measured using a microplate reader (apparatus: SpextraMax iD5, measurement mode: LUM endpoint, MOLECULAR DEVICE). In addition, the number of live reporter bacteria in the solution after incubation was measured by colony counting method.

[0084] As a blank, an aqueous solution containing 10% by volume of ethanol was used instead of the sample, and an aqueous solution containing 10% by volume of ethanol was used instead of the HMF-containing solution, and the luminescence intensity (blank luminescence intensity) and viable cell count were measured under the same conditions as above.

[0085] As a negative control, an aqueous solution containing 10% by volume of ethanol was used instead of the specimen, and the luminescence intensity (luminescence intensity of the negative control) and viable cell count were measured under the same conditions as above.

[0086] As a positive control, a BMF-containing solution was used instead of the specimen, and the luminescence intensity (luminescence intensity of the positive control) and viable cell count were measured under the same conditions as above.

[0087] The AI-2 inhibition rate was calculated from the measured luminescence intensity according to the following formula.

number

[0088] 2. Test Results The results are shown in Table 1. Star fruit leaf extract, carrot extract, and Phellodendron bark leaf extract did not show any inhibitory activity against AI-2 when used alone. In contrast, when star fruit leaf extract and carrot extract were used in combination, and when star fruit leaf extract and Phellodendron bark extract were used in combination, excellent inhibitory activity against AI-2 was observed.

[0089] [Table 1]

[0090] Test Example 2: Verification of the inhibitory effect of acne bacteria on biofilm formation 1. Test Method The biofilm formation inhibitory effect was evaluated using Propionibacterium acnes. The test materials and measurement conditions used are as follows.

[0091] (1) Test materials ·Acne bacteria Cutibacterium acnes (NBRC 107605) was used as the acne bacterium.

[0092] 2x BHI liquid medium 37 g of Brain Heart Infusion (BHI) broth (Becton Dickinson Japan) was mixed with 500 mL of distilled water and sterilized by high-pressure steam (121°C, 15 min) to obtain 2x BHI liquid medium.

[0093] ·BHI agar medium Brain Heart Infusion medium (Becton Dickinson Japan Co., Ltd.) was used to obtain BHI agar medium according to the manufacturer's protocol.

[0094] Specimen Each plant extract was added to distilled water at a concentration 2.5 times that shown in Table 2 to prepare various samples.

[0095] (2) Measurement conditions Propionibacterium acnes was smeared on BHI agar medium, placed in an Anaerobox containing Anaeropack, and cultured at 37°C for 3 days under anaerobic conditions. The cultured Propionibacterium acnes was then suspended in 2x BHI liquid medium and the OD 600 = 0.02 to 0.03 to obtain a test bacterial solution. 2.5 mL of the test bacterial solution, 0.5 mL of an aqueous solution containing 10% by weight of glucose, and 2 mL of the sample were mixed. At this point, the sample was diluted 2.5 times. The final concentration listed in Table 2 is the concentration of the sample at this point. Then, 200 μL of the obtained mixture was added to each well (6 wells per sample) of a 96-well microtiter plate, placed in an Anaerobox containing Anaeropack, and cultured at 37 ° C for 7 days under anaerobic conditions in a 5% CO2 incubator. Then, for one well, pipetting was performed until all the biofilm on the bottom was detached and suspended, and the number of viable bacteria was measured by the colony counting method (BHI agar medium, Anaerobox containing Anaeropack, 37 ° C, 5 days). For the remaining wells, the culture solution was gently removed so as not to damage the biofilm, and then 0.3 mL of PBS was added and the supernatant was gently removed again. The 96-well microtiter plate was then left to dry in a safety cabinet for 1 hour, allowing the biofilm to adhere to the bottom of the wells. Then, 160 μL of 0.1% crystal violet staining solution was added to the wells and left to stand for 10 minutes. The staining solution was then removed, and the wells were washed twice with 200 μL of PBS. Then, 200 μL of 99.5% ethanol was added, and the staining solution was extracted by pipetting. The resulting extract was appropriately diluted, and the absorbance at 595 nm (absorbance of the sample) was measured.

[0096] As a blank, 1x BHI liquid medium (2x BHI liquid medium diluted 2-fold with sterile distilled water) was used instead of the test bacterial solution and the specimen, and the viable cell count and absorbance at 595 nm (blank absorbance) were measured under the same conditions as above.

[0097] As a control, distilled water was used instead of the specimen, and the viable cell count, absorbance at 595 nm (absorbance of the control) and viable cell count were measured under the same conditions as above.

[0098] The biofilm formation inhibition rate was calculated from the measured absorbance value at 595 nm according to the following calculation formula.

number

[0099] 2. Test Results The results are shown in Table 2. Star fruit leaf extract, carrot extract, and Phellodendron bark extract did not show any inhibitory effect on the formation of biofilms caused by acne bacteria when used alone. In contrast, when star fruit leaf extract and carrot extract were used in combination, and when star fruit leaf extract and Phellodendron bark extract were used in combination, they showed a significantly more significant inhibitory effect on the formation of biofilms caused by acne bacteria without exhibiting antibacterial activity against acne bacteria. As shown in the above-mentioned Test Example 1, the combined use of star fruit leaf extract and carrot extract, and the combined use of star fruit leaf extract and Phellodendron bark extract have AI-2 inhibitory activity, and therefore it is considered that the quorum sensing of acne bacteria is inhibited by AI-2 inhibition, and the formation of biofilms is suppressed.

[0100] [Table 2]

[0101] Test Example 3: Verification of the effect of disinfectants on the bactericidal action 1. Test Method The bactericidal activity against free-floating P. acnes and P. acnes in a biofilm was evaluated. The test materials and measurement conditions used are as follows.

[0102] (1) Test materials ·Acne bacteria Cutibacterium acnes (NBRC 107605) was used as the acne bacterium.

[0103] ·BHI agar medium Brain Heart Infusion medium (Becton Dickinson Japan Co., Ltd.) was used to obtain BHI agar medium according to the manufacturer's protocol.

[0104] 2x BHI liquid medium 37 g of Brain Heart Infusion (BHI) broth (Becton Dickinson Japan) was mixed with 500 mL of distilled water and sterilized by high-pressure steam (121°C, 15 min) to obtain 2x BHI liquid medium.

[0105] Specimen Samples having the compositions shown in Table 3 were prepared.

[0106] [Table 3]

[0107] (2) Test conditions (2-1) Method for evaluating the bactericidal effect against airborne acne bacteria Propionibacterium acnes was smeared on BHI agar medium, placed in an Anaerobox containing Anaeropack, and cultured at 37°C for 3 days under anaerobic conditions. The cultured Propionibacterium acnes was then suspended in 2x BHI liquid medium and the OD 600 = 0.02 to 0.03 to obtain a test bacteria liquid. 2.5 mL of the obtained test bacteria liquid, 0.5 mL of a 10 wt% glucose aqueous solution, and 2 mL of distilled water were mixed to obtain a suspension for growing P. acnes. The suspension for growing P. acnes was placed in a sterile test tube, placed in an Anaerobox containing an Anaeropack, and cultured at 37°C for 7 days under anaerobic conditions in a 5% CO2 incubator.

[0108] After 7 days of cultivation, the culture solution was gently pipetted and collected in a 50 mL tube, and stirred. Then, it was subjected to centrifugation, the supernatant was removed, and the precipitated bacteria were suspended in 10 mL of sterile distilled water, and centrifuged again. Then, the supernatant was removed, and the precipitated bacteria were suspended in 10 mL of sterile distilled water, and 2.0 × 10 8 ~1.0×10 9A bacterial solution of CFU / mL was prepared. 0.1 mL of the prepared bacterial solution was added to each well (6 wells per sample) of a 96-well microtiter plate, and 0.1 mL of a control solution (aqueous solution containing 36% by weight of DMSO (dimethyl sulfoxide)) or a bactericide solution (aqueous solution containing 0.2% by weight of isopropyl methylphenol and 36% by weight of DMSO) was added and stirred by pipetting. Then, the mixture was left to stand at 37°C for 30 minutes. After the static culture, the number of live bacteria of P. acnes in the suspension in each well was measured by colony counting method (using BHI agar medium and an Anaerobox containing Anaeropack, 37°C, 3 to 5 days). The bactericidal activity value was calculated according to the following formula.

number

[0109] (2-2) Method for evaluating the bactericidal effect against P. acnes in biofilms Propionibacterium acnes was smeared on BHI agar medium, placed in an Anaerobox containing Anaeropack, and cultured at 37°C for 3 days under anaerobic conditions. The cultured Propionibacterium acnes was then suspended in 2x BHI liquid medium and the OD 600=0.02 to 0.03 to obtain a test bacterial solution. 2.5 mL of the obtained test bacterial solution, 0.5 mL of an aqueous solution containing 10% glucose by weight, and 2 mL of a specimen were mixed to prepare a suspension for biofilm formation. Next, 200 μL of the suspension for biofilm formation obtained above was added to each well (6 wells per specimen) of a 96-well microtiter plate, placed in an Anaerobox containing an Anaeropack, and cultured at 37 ° C. for 7 days under anaerobic conditions in a 5% CO2 incubator to form a biofilm in the well. Then, the culture supernatant was gently removed so as not to damage the biofilm in the well. Next, 0.3 mL of PBS was added to the well, and the supernatant was gently removed so as not to damage the biofilm. Then, 200 μL of a control solution (aqueous solution containing 18% by weight of DMSO (dimethyl sulfoxide)) or a disinfectant solution (aqueous solution containing 0.1% by weight of isopropyl methylphenol and 18% by weight of DMSO) was added to the well, and the well was cultured at 7 ° C. for 30 minutes. Next, the biofilm on the bottom of the well was pipetted until it was completely detached and suspended to prepare a biofilm-derived suspension, and the viable cell count of the biofilm-derived suspension was measured by colony counting method (using BHI agar medium and Anaerobox containing Anaeropack, 37℃, 3-5 days). The bactericidal activity value was calculated according to the following formula.

number

[0110] 2. Test Results The results are shown in Table 4. Isopropyl methylphenol showed excellent bactericidal activity against floating acne bacteria, but almost no bactericidal activity was observed against acne bacteria in biofilms. In contrast, isopropyl methylphenol showed excellent bactericidal activity against acne bacteria in biofilms formed in the presence of star fruit leaf extract and carrot extract or phellodendron bark extract. That is, the test results show that the combined use of star fruit leaf extract and carrot extract or phellodendron bark extract has the effect of enhancing the action of the bactericide, particularly the effect of enhancing the action of the bactericide against bacteria present in biofilms.

[0111] [Table 4]

Claims

1. A composition for inhibiting autoinducer-2 comprising (A) starfruit leaf extract and (B) carrot extract and / or phellodendron bark extract.

2. The composition for inhibiting autoinducer-2 according to claim 1, further comprising (C) a fungicide.

3. The composition for inhibiting autoinducer-2 according to claim 1 or 2, which is used to inhibit autoinducer-2 of at least one bacterium selected from the group consisting of Cutibacterium bacteria, Pseudomonas bacteria, and Vibrio bacteria.

4. The composition for inhibiting autoinducer-2 according to claim 1 or 2, which is an external preparation for skin.

5. The composition for inhibiting autoinducer-2 according to claim 1 or 2, which is applied to skin where prevention or treatment of acne is desired.

6. A composition for inhibiting biofilm formation comprising (A) starfruit leaf extract and (B) carrot extract and / or phellodendron bark extract.

7. The composition for inhibiting biofilm formation according to claim 6, further comprising (C) a bactericide.

8. The composition for inhibiting biofilm formation according to claim 6 or 7, which is used to inhibit biofilm formation by bacteria of the genus Cutibacterium and / or bacteria of the genus Pseudomonas.

9. A composition for inhibiting biofilm formation as described in claim 6 or 7, which is applied to skin where acne prevention or treatment is desired.

10. A composition for external use comprising (A) starfruit leaf extract, (B) carrot extract and / or Phellodendron bark extract, and (C) a bactericide.

11. The topical composition according to claim 10, which is used to kill bacteria in a biofilm.

12. The composition for external use according to claim 11, which is used to kill Cutibacterium bacteria and / or Pseudomonas bacteria in a biofilm.

13. The composition for external use according to claim 10 or 11, which is an external preparation for skin.

14. The composition for external use according to claim 13, which is used for the prevention or treatment of acne.

Citation Information

Patent Citations

  • Autoinducer-2 inhibitor, and preventing and / or therapeutic agent of periodontal disease or caries disease

    JP2012097036A

  • Effect of treatment with 4,5-dihydroxy- 2-cyclopenten-1-one (DHCP) on gene expression and quorum-sensing in bacteria

    WO2003077844A2